DNDi is grateful to the donors listed below for funding its HAT Global program and to UK aid, UK; the Swiss Agency for Development and Cooperation (SDC), Switzerland; and MSF International for funding its overall mission. Fexinidazole for Trypanosoma brucei gambiense: Bill & Melinda Gates Foundation; Brian Mercer Trust; Dutch Ministry of Foreign Affairs (DGIS), the Netherlands; Else Kröner Fresenius Award for Development Cooperation in Medicine 2020; European and Developing Countries Clinical Trials Partnership Association (EDCTP2) programme supported by the European Union (CSA2018H-2526, Fex-g-HAT); Federal Ministry of Education and Research (BMBF) through KfW, Germany; French Development Agency (AFD), France; German Corporation for International Cooperation (GIZ) on behalf of the Government of the Federal Republic of Germany, Germany; Ministry for Europe and Foreign Affairs (MEAE), France; Ministry of Health (Development of the Health System Project (PDSS), financed by the World Bank), DRC; Norwegian Agency for Development Cooperation (Norad), Norwegian Ministry of Foreign Affairs, as part of Norway’s in-kind contribution to the European and Developing Countries Clinical Trials Partnership, Norway; Republic and Canton of Geneva, International Solidarity Service, Switzerland; Spanish Agency for International Development Cooperation (Aecid), Spain; Stavros Niarchos Foundation; Takeda Pharmaceutical Company Limited; The ELMA Foundation; UBS Optimus Foundation, and Other private foundations and individuals.
Valverde Mordt O , 2020. Latest advances in control of sleeping sickness: towards elimination. Bull Netherlands Soc Trop Med Int Heal 58: 6–8.
De Koning HP , 2020. The drugs of sleeping sickness: their mechanisms of action and resistance, and a brief history. Trop Med Infect Dis 5: 14.
Bronner U , Doua F , Ericsson Ö , Gustafsson LL , Miézan TW , Rais M , Rombo L , 1991. Pentamidine concentrations in plasma, whole blood and cerebrospinal fluid during treatment of Trypanosoma gambiense infection in Côte d’Ivoire. Trans R Soc Trop Med Hyg 85: 608–611.
- Search Google Scholar
- Export Citation
Bronner U Doua F Ericsson Ö Gustafsson LL Miézan TW Rais M Rombo L 1991. Pentamidine concentrations in plasma, whole blood and cerebrospinal fluid during treatment of. Trans R Soc Trop Med Hyg Trypanosoma gambienseinfection in Côte d’Ivoire 85: 608– 611. 1780988
Priotto G et al.2009. Nifurtimox-eflornithine combination therapy for second-stage African Trypanosoma brucei gambiense trypanosomiasis: a multicentre, randomised, phase III, non-inferiority trial. Lancet 374: 56–64.
Franco JR , Cecchi G , Priotto G , Paone M , Diarra A , Grout L , Simarro PP , Zhao W , Argaw D , 2020. Monitoring the elimination of human African trypanosomiasis at continental and country level: update to 2018. PLoS Negl Trop Dis 14: e0008261.
Molyneux DH , 2016. The London declaration on neglected tropical diseases: 5 years on. Trans R Soc Trop Med Hyg 110: 623–625.
Jennings FW , Urquhart GM , 1983. The use of the 2 substituted 5-nitroimidazole, fexinidazole (Hoe 239) in the treatment of chronic T. brucei infections in mice. Z Parasitenkd 69: 577–581.
Torreele E , Bourdin Trunz B , Tweats D , Kaiser M , Brun R , Mazué G , Bray MA , Pécoul B , 2010. Fexinidazole—a new oral nitroimidazole drug candidate entering clinical development for the treatment of sleeping sickness. PLoS Negl Trop Dis 4: e923.
Tarral A et al.2014. Determination of an optimal dosing regimen for fexinidazole, a novel oral drug for the treatment of human African trypanosomiasis: first-in-human studies. Clin Pharmacokinet 53: 565–580.
Mesu VKBK et al.2018. Oral fexinidazole for late-stage African Trypanosoma brucei gambiense trypanosomiasis: a pivotal multicentre, randomised, non-inferiority trial. Lancet 391: 144–154.
Mbo F , Mutombo W , Ngolo D , Kabangu P , Valverde Mordt O , Strub Wourgaft N , Mwamba E , 2020. How clinical research can contribute to strengthening health systems in low resource countries. Trop Med Infect Dis 5: 48.
Coleman CH et al.2015. Improving the quality of host country ethical oversight of international research: the use of a collaborative ‘pre-review’ mechanism for a study of fexinidazole for human African trypanosomiasis. Developing World Bioeth 15: 241–247.
Mpanya A et al.2015. From health advice to taboo: community perspectives on the treatment of sleeping sickness in the Democratic Republic of Congo, a qualitative study. PLoS Negl Trop Dis 9: e0003686.
World Health Organization , 2021. Human African Trypanosomiasis (Sleeping Sickness). Geneva, Switzerland: WHO. Available at: https://www.who.int/data/gho/data/themes/topics/human-african-trypanosomiasis. Accessed October 7, 2021.
Couderc-Pétry M , Eléfant E , Wasunna M , Mwinga A , Kshirsagar NA , Strub-Wourgaft N , 2020. Inclusion of women susceptible to and becoming pregnant in preregistration clinical trials in low- and middle-income countries: a proposal for neglected tropical diseases. PLoS Negl Trop Dis 14: e0008140.
- Search Google Scholar
- Export Citation
Couderc-Pétry M Eléfant E Wasunna M Mwinga A Kshirsagar NA Strub-Wourgaft N 2020. Inclusion of women susceptible to and becoming pregnant in preregistration clinical trials in low- and middle-income countries: a proposal for neglected tropical diseases. PLoS Negl Trop Dis 14: e0008140. 32525876